现在的位置: 首页时讯速递, 进展交流>正文
[Intensive Care Med发表论文]:急性呼吸功能衰竭的可重复临床分型
2026年08月22日 时讯速递, 进展交流 [Intensive Care Med发表论文]:急性呼吸功能衰竭的可重复临床分型已关闭评论

Reproducible clinical archetypes in acute respiratory failure: a multi-cohort trajectory analysis

Marshall, D.C., Green, A.D., Komorowski, M. et al

Intensive Care Med (2026)

https://doi.org/10.1007/s00134-026-08441-2

Abstract

Purpose

Acute hypoxemic respiratory failure (AHRF) is common and biologically heterogeneous. Static phenotyping at a single time point does not capture illness evolution and risks stage-mixing; reproducible clinical course archetypes may address this. We aimed to identify, externally validate, and predict trajectory classes (TCs) of persistent AHRF.

Methods

We analyzed MIMIC-IV (derivation; n = 3938) and two external validation cohorts (UK/Netherlands; n = 6480) comprising adults with PaO2/FiO2 < 300 mmHg and PEEP ≥ 5 cmH2O for ≥ 72 h. Daily mean PaO2/FiO2 to day 14 and time to ICU discharge/death were jointly modelled using a competing-risk latent class mixed model. Early TC prediction used a 12-variable XGBoost model. We explored prevalence of ARDS and hyperinflammatory subphenotypes between TCs.

Results

A four-class model provided optimal fit: (TC1) early recovery (0.3% 14-day mortality); (TC2) stable persistence (8% 14-day mortality); (TC3) biphasic improvement–deterioration (17% 14-day mortality); and (TC4) rapid decline (100% 14-day mortality). These archetypes generalized to external cohorts with high assignment certainty. TCs demonstrated distinct patterns in other clinical biomarker trajectories. TC4 was enriched for the hyperinflammatory subphenotype (41–53%), while TC2 was most common in patients with ARDS (50%). Early TC prediction models achieved mean AUCs ≥ 0.78 (0.70–0.86) by day 3 in external validation.

Conclusions

Four reproducible oxygenation archetypes capture the 14-day course of persistent respiratory failure. By providing early prognostic value distinct from static baseline severity, these trajectories have the potential to guide therapeutic strategies, reduce patient heterogeneity in trials, and direct biological phenotyping.

抱歉!评论已关闭.

×
腾讯微博